Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview

Schizophrenia is a chronic, severe mental disorder associated with significant disability, caregiver burden, and public health impact, particularly in low- and middle-income countries such as India. While multiple international clinical practice guidelines (CPGs) exist, contextual differences in illness presentation, sociocultural factors, health-care infrastructure, and resource availability necessitate region-specific guidance. This CPG provides a comprehensive, stage-based overview of the assessment and management of schizophrenia, with an emphasis on applicability to the Indian context. The document synthesizes available evidence, existing guideline recommendations, and expert clinical consensus to outline pragmatic approaches across the illness trajectory, including the prodromal phase, first-episode psychosis, multiepisode relapsing-remitting course, and treatment-resistant schizophrenia. Detailed recommendations are provided for clinical assessment, use of standardized rating scales, physical and laboratory investigations, and identification of comorbid medical and psychiatric conditions at each stage. Pharmacological strategies emphasize rational antipsychotic use, including early intervention principles, maintenance treatment, long-acting injectable antipsychotics, therapeutic drug monitoring-particularly for clozapine-and evidence-based augmentation approaches in treatment resistance. The guideline also addresses emergency management, antipsychotic switching strategies, and the judicious use of combination and adjuvant psychotropic therapies. Equally, it highlights the critical role of psychological and psychosocial interventions, family involvement, community-based care, and rehabilitation services in achieving functional recovery. Special attention is given to implementation challenges and adaptations relevant to Indian clinical settings, including cost, accessibility, family structures, and public mental health systems. Overall, this guideline aims to support clinicians in delivering individualized, evidence-informed, and contextually appropriate care for persons with schizophrenia, thereby improving long-term outcomes and quality of life.